ScholarIQanswers from OpenAlex

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe

PaperCitations, authors & open-access status

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe have?

ScholarIQcitation count

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe has 6 citations in the OpenAlex counts ScholarIQ stores.

When was Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe published?

ScholarIQyear

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe has 2023 year in the ScholarIQ index.

What is the open-access status of Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe?

ScholarIQoa status

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe has hybrid oa status in the ScholarIQ index.

What is the DOI of Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe?

ScholarIQdoi

The DOI for Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe is on the source record.

What is the PMID of Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe?

ScholarIQpmid

The PMID for Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe is on the source record.

What is the OpenAlex record for Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe?

ScholarIQopenalex

The OpenAlex for Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial